Axsome Therapeutics (AXSM) Equity Average (2022 - 2025)
Axsome Therapeutics (AXSM) has disclosed Equity Average for 4 consecutive years, with $81.0 million as the latest value for Q4 2025.
- Quarterly Equity Average rose 8.08% to $81.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $81.0 million through Dec 2025, up 8.08% year-over-year, with the annual reading at $72.7 million for FY2025, 41.41% down from the prior year.
- Equity Average hit $81.0 million in Q4 2025 for Axsome Therapeutics, up from $73.4 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $274.2 million in Q3 2023 to a low of $14.9 million in Q2 2022.
- Historically, Equity Average has averaged $118.8 million across 4 years, with a median of $97.9 million in 2024.
- Biggest five-year swings in Equity Average: skyrocketed 1206.54% in 2023 and later plummeted 67.44% in 2024.
- Year by year, Equity Average stood at $133.5 million in 2022, then soared by 72.52% to $230.2 million in 2023, then tumbled by 67.44% to $75.0 million in 2024, then grew by 8.08% to $81.0 million in 2025.
- Business Quant data shows Equity Average for AXSM at $81.0 million in Q4 2025, $73.4 million in Q3 2025, and $63.1 million in Q2 2025.